AUTHOR=Ma Xiaoting , Liu Xiu , Ou Kai , Zhang Manman , Gao Lizhen , Yang Lin 

TITLE=Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1151178

DOI=10.3389/fonc.2023.1151178

ISSN=2234-943X

ABSTRACT=Pancreatic cancer is a leading cause of cancer deaths; treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and observed tumor shrinkage and a decreased CA19-9 level. The progression-free survival following treatment with furmonertinib was 4.7 months and no adverse effects were observed; however, the patient did not benefit from subsequent nimotuzumab-based therapy. Targeted therapy driven by the detection of genetic signatures in this patient with refractory advanced pancreatic cancer had a potential clinical benefit.